GET DAILY SIGNALSWhy Is Nano-X Imaging (NNOX) Stock Down 3.54% Today?
Key Takeaways
- NNOX shares fell roughly 3.5% in Monday's session, sliding to about $0.23 from a prior close of $0.2402.
- The primary pressure is ongoing concern over the company's cash runway, going-concern disclosure, and looming shareholder vote on a reverse split and share-capital increase.
- Secondary drivers include a recent CFO departure, a Nasdaq minimum-bid-price deficiency, weak quarterly results, and dilution fears ahead of an upcoming special meeting.
- The stock remains deep in a downtrend, trading near its 52-week low and well below major moving averages.
- Traders are watching the November 18 special shareholder meeting and third-quarter results expected later this month.
- For deeper analysis, explore Price Targets, Earnings, and Forecast pages for NNOX.
- For AI-driven trading ideas across thousands of tickers, visit Trending AI Robots.
Opening Summary
NNOX, the Nasdaq-listed stock of Nano-X Imaging Ltd, an Israel-based medical imaging company developing digital X-ray technology and AI-powered imaging software, extended its decline on Monday. Shares traded at roughly $0.2317, down about 3.5% from Friday's closing level of $0.2402, confirming a downward move as selling pressure persisted in the speculative micro-cap name. The decline reflects continued unease over the company's balance sheet and the corporate actions it has asked shareholders to approve.
Going-Concern and Cash Burn Concerns
The most persistent headwind weighing on NNOX shares is the company's own disclosure about its financial runway. In preliminary third-quarter figures, Nano-X indicated cash, equivalents, and deposits had fallen to roughly $26 million as of September 30, down from about $60 million at the end of 2025. Management stated that its current liquidity is not sufficient to fund operations under current plans for at least a year, raising substantial doubt about the company's ability to continue as a going concern. That warning has kept the stock under sustained selling pressure as investors discount the risk of additional capital raises.
Reverse Split and Dilution Fears
Ahead of a special general meeting scheduled for November 18, 2026, Nano-X is seeking shareholder approval to increase its authorized share capital and to establish a framework for a reverse stock split in a range of 1-for-20 to 1-for-50. While a reverse split is intended to address the Nasdaq minimum-bid-price deficiency, the accompanying expansion of authorized shares has intensified dilution concerns. With the stock trading near its cash value and the company needing funding, investors are wary that new share issuance could further erode existing holders' positions. An activist investor holding a substantial stake has publicly indicated opposition to the capital increase, adding uncertainty to the vote.
Leadership and Listing Pressures
Compounding the fundamental concerns, Nano-X disclosed in late October that its chief financial officer would step down for medical reasons, prompting a successor search during a critical period of capital planning. Separately, the company has been working to regain compliance with Nasdaq's $1.00 minimum-bid-price requirement, with the stock trading well below that threshold. These governance and listing issues have added to investor caution and contributed to the stock's slide toward its 52-week low.
Market Context and Trading Activity
NNOX has been trading in a pronounced downtrend, with shares near the lower end of a range that saw a 52-week low around $0.21 in the prior session. Recent sessions have featured elevated turnover relative to the stock's average volume as investors reposition ahead of the special meeting and the upcoming earnings print. The weakness in the name is largely company-specific, driven by its cash position and financing outlook, rather than a broad move in the medical-device or imaging sector. Technically, the stock remains below its major moving averages, with no sustained rebound signal yet evident.
What Comes Next for NNOX
The near-term catalysts for NNOX are clear but uncertain. The November 18 special meeting will determine whether shareholders approve the reverse split and the increase in authorized capital, a decision that could materially shape the company's financing strategy. Nano-X is also expected to report third-quarter results in the coming weeks, with investors focused on cash burn, revenue progression, and any update to the going-concern language. Risks include further dilution, execution challenges in commercializing its imaging systems, and the outcome of pending shareholder litigation. Until the company demonstrates a credible path to stabilizing its cash position, volatility is likely to remain elevated.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing traders to review a range of approaches rather than a single style. Explore the Trending AI Robots page to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NNOX's RSI Oscillator stays in oversold zone for 21 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
NNOX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for NNOX turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 43 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NNOX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NNOX entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.260) is normal, around the industry mean (4.142). P/E Ratio (-0.140) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.266) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. NNOX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NNOX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development of medical imaging systems
Industry MedicalNursingServices
Advertisement